Breast Cancer Study
NSABP B-46 I/USOR 07132: A Phase III Clinical trial Comparing the combination of TC plus Bevacizumab to TC alone and to TAC for women with node-positive or high -risk node negative , HER2-negative Breast Cancer
Protocol ID
Protocol Description
The main purpose of this study is to learn if adding a drug called bevacizumab to treatment with two standard chemotherapy drugs for early stage HER2-negative breast cancer will prevent breast cancer from returning. Bevacizumab is called a targeted therapy because it works by blocking a protein called vascular endothelial growth factor (VEGF) that helps new blood vessels form. Without new blood vessels, the growth of the tumor is slowed.
A second purpose of this study is to learn if adding bevacizumab to treatment with docetaxel and cyclophosphamide will help women with HER2-negative breast cancer live longer. Another purpose of this study is to learn if adding bevacizumab to docetaxel and cyclophosphamide works better in treating breast cancer than a combination of three chemotherapy drugs (docetaxel, doxorubicin, and cyclophosphamide). This study will also compare the two chemotherapy combinations given without bevacizumab to see if one chemotherapy combination is better than the other in treating breast cancer. The researchers also want to learn about the side effects of the combination of drugs used in this study.
Eligibility Criteria
Patients with breast cancer
Primary Investigator(s)
- Lora Weiselberg, MD